RxDoctor Payments Data

Caitlin Crowell, PA

Physician Assistant · Youngstown, OHNPI 1003174905

Payments from drug & device makers

$2,895in general payments, 2019–2025

Across 148 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$344
  • Boehringer Ingelheim$316
  • Amgen$291
  • Novartis$263
  • Abbott$233
  • E.r. Squibb & Sons, L.L.C.$219
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,895100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,895 in reported general payments places this provider in the 90th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$17,767
Medicare patients
107
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan221$234,913
JardianceEmpagliflozin191$169,235
EliquisApixaban87$75,535
VerquvoVericiguat13$16,681
XareltoRivaroxaban12$13,632
BrilintaTicagrelor12$8,630
CorlanorIvabradine Hcl11$4,864
Metoprolol Succinate201$1,878
Potassium Chloride73$1,854
Atorvastatin Calcium132$1,386
Furosemide241$1,026
ClopidogrelClopidogrel Bisulfate76$947
Isosorbide Mononitrate ErIsosorbide Mononitrate40$809
Torsemide44$782
Amiodarone Hcl37$747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$263$234,913221 claims
Boehringer IngelheimJardiance$316$169,235191 claims
PfizerEliquis$48$75,53587 claims
MerckVerquvo$116$16,68113 claims
Johnson & JohnsonXarelto$344$13,63212 claims
AstraZenecaBrilinta$159$8,63012 claims
AmgenCorlanor$291$4,86411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →